期刊
EUROPEAN JOURNAL OF PHARMACOLOGY
卷 741, 期 -, 页码 304-310出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.ejphar.2014.08.004
关键词
Parkinson's disease; L-Dopa; Dyskinesia; NMDA; 5HT(1A) and H-3 receptors
资金
- Solvay Pharmaceuticals Research Laboratories
The treatment of dyskinesia in Parkinson's disease remains poor but H-3 receptor agonists have been suggested as a novel pharmacological approach. We examined the effects of the H-3 agonist, immepip, in 6-OHDA-lesioned rats exhibiting AIMs (abnormal involuntary movements), a rat analogue of dyskinesia, in response to L-dopa compared to the known anti-dyskinetic agents amantadine, MK-801 and 8-OHDPAT. We then attempted to extend these studies in to dyskinetic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treated common marmosets. Amantadine, MK-801 and 8-OHDPAT all dose-dependently reduced L-dopa-induced axial, lingual and oral (ALO) AIMs in 6-OHDA-lesioned animals accompanied by a reduction in contralateral rotation with higher doses of amantadine and MK-801. By contrast, immepip had no effect on AIMs expression or contralateral rotation. In the MPTP-treated common marmoset exhibiting dyskinesia immepip alone induced retching and in combination with L-dopa administered subcutaneously or orally induced the rapid onset of retching and vomiting which was not controlled by pretreatment with domperidone. Administration of the unrelated H-3 agonist, imetit had the same effect. Despite causing negative side-effects, it appears that both agonists reduced the antiparkinsonian response to L-dopa resulting in reduced dyskinesia. H-3 agonists appear unlikely candidates for the treatment of dyskinesia in PD based on lack of evidence of efficacy and potential adverse effects. Crown Copyright (C) 2014 Published by Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据